Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company [Yahoo! Finance]
Astria Therapeutics, Inc. (ATXS)
Company Research
Source: Yahoo! Finance
The top 7 shareholders own 52% of the company Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock If you want to know who really controls Astria Therapeutics, Inc. ( NASDAQ:ATXS ), then you'll have to look at the makeup of its share registry. With 53% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's delve deeper into each type of owner of Astria Therapeutics, beginning with the chart below. Check out our latest analysis for Astria Therapeutics What Does The Institutional Ownership Tell Us About Astria Therapeutics? Instit
Show less
Read more
Impact Snapshot
Event Time:
ATXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATXS alerts
High impacting Astria Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATXS
News
- Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target lowered by analysts at HC Wainwright from $18.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Astria Therapeutics Appoints Sunil Agarwal to Its Board of DirectorsBusiness Wire
- Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
ATXS
Earnings
- 11/13/23 - Miss
ATXS
Sec Filings
- 4/22/24 - Form ARS
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form DEF
- ATXS's page on the SEC website